CoChat
Sign Up
Cited by 614Advanced MRI Techniques and ApplicationsMRI in cancer diagnosisCharacterization and Applications of Magnetic Nanoparticles

Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications

Reimer, Peter, Balzer, Thomas·2003·European Radiology
DOI 10.1007/s00330-002-1721-7
Open this paper in CoChat — free account

Abstract

Ferucarbotran (Resovist) is the second clinically approved superparamagnetic iron oxide developed for contrast-enhanced MRI of the liver. The purpose of this review is to provide an overview on the properties, clinical development, and application of ferucarbotran. Safety data obtained during clinical phases I-III revealed a total of 162 adverse events within 1053 patients, of which 75 were classified as possibly, probably, or definitely drug related. The majority of events occurred within the first 3 h (73 of 75) and was of mild intensity. The agent significantly improves the detection of hypovascular focal liver lesions with a comparable sensitivity in lesion detection to CTAP but without a relevant loss in specificity. Furthermore, ferucarbotran leads to a significant improvement of the sensitivity for lesion classification and characterization of the most frequent liver lesions. Contrast-enhanced MRA is not feasible and the angiographic effect is not sufficient to allow for postprocessing of data into maximum intensity projections. Intraindividual studies at low-field (0.2 T) and high-field (1.5 T) showed similar rates for lesion detection. The time window for contrast-enhanced MRI of the liver is at least 1 day up to 4 days. The compound can be regarded as safe and well tolerated. Even bolus injections caused no cardiovascular side effects, lumbar back pain, or clinically relevant laboratory changes. The examination time can be kept short with T1- and T2-weighted pre-contrast sequences, dynamic MRI over 10 min, and finally accumulation phase T2-weighted MRI. Patients who may benefit in particular are surgical candidates for resection, transplantation, or interventional therapies, and patients with liver cirrhosis and/or suspected hepatocellular carcinoma to either exclude malignancy or to define the extent of disease, the location of lesions, and the type of newly detected lesions.

Integrity signals

Registry

Crossref · 10.1007/s00330-002-1721-7

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ferucarbotran and ferumoxide have been available on the market and under clinical investigation.

    “Available on the market and under clinical investigation have been ferucarbotran (Resovist®) and ferumoxide (Feridex® (USA), Endorem® (EU); see Table 1 [146, 147].”

    From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [147]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Reimer, P., & Balzer, T.
Affiliations
Städtisches Klinikum Karlsruhe (DE)
Corresponding author
Reimer, Peter
ORCID
Reimer, Peter
Venue
European Radiology
Publisher
Springer Science and Business Media LLC
Published
2003-06
Volume
13
Issue
6
Pages
1266-1276
ISSN
  • 0938-7994 (ISSN-L)
  • 1432-1084
DOI
10.1007/s00330-002-1721-7
OpenAlex
W1560609297
Cited by
614
References
42
Citations by year
2026: 10 · 2025: 25 · 2024: 26 · 2023: 29 · 2022: 33 · 2021: 31 · 2020: 37 · 2019: 26 · 2018: 35 · 2017: 34 · 2016: 29 · 2015: 35 · 2014: 42 · 2013: 30 · 2012: 28
FWCI
13.38
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • European Radiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
  • Physical Sciences › Engineering › Biomedical Engineering › Characterization and Applications of Magnetic Nanoparticles
Keywords
ferucarbotran, Resovist, superparamagnetic iron oxide nanoparticles, contrast-enhanced MRI, hepatocellular carcinoma, liver lesion detection, drug safety, adverse events, liver cirrhosis, lesion characterization
MeSH terms
Contrast Media, Dextrans, Humans, Iron, Liver, Liver Diseases, Liver Neoplasms, Magnetic Resonance Imaging, Oxides, Safety, Time Factors, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Magnetic Resonance Angiography, Ferrosoferric Oxide, Magnetite Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review